GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » Selling, General, & Admin. Expense

Synaptogenix (Synaptogenix) Selling, General, & Admin. Expense : $5.38 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Synaptogenix's selling, general, & admin. expense for the three months ended in Mar. 2024 was $1.08 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $5.38 Mil.


Synaptogenix Selling, General, & Admin. Expense Historical Data

The historical data trend for Synaptogenix's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix Selling, General, & Admin. Expense Chart

Synaptogenix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
9.84 8.09 8.28 9.81 6.34

Synaptogenix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 1.52 1.22 1.56 1.08

Competitive Comparison of Synaptogenix's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Synaptogenix's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synaptogenix's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synaptogenix's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Synaptogenix's Selling, General, & Admin. Expense falls into.



Synaptogenix Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synaptogenix  (NAS:SNPX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Synaptogenix Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Synaptogenix's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Synaptogenix (Synaptogenix) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Executives
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer director C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon director, officer: Chief Scientific Officer C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman director, officer: Chief Executive Officer 18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry director C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010